Scarica l'app Stockscreener
3.97
9.67%
0.35
Dopo l'orario di chiusura:
3.94
-0.03
-0.76%
Precedente Chiudi:
$3.62
Aprire:
$3.86
Volume 24 ore:
448.79K
Relative Volume:
1.64
Capitalizzazione di mercato:
$189.00M
Reddito:
$114.70K
Utile/perdita netta:
$-37.06M
Rapporto P/E:
-0.9943
EPS:
-3.9929
Flusso di cassa netto:
$-30.69M
1 W Prestazione:
+6.15%
1M Prestazione:
-0.25%
6M Prestazione:
+102.55%
1 anno Prestazione:
+4.47%
Intervallo 1D:
$3.65
$4.01
Intervallo di 1 settimana:
$3.56
$4.01
Portata 52W:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Confronta SABS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.97 | 172.34M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Iniziato | Leerink Partners | Outperform |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
Two veteran drug leaders join the board behind a new Type 1 diabetes therapy - Stock Titan
SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential - Investing.com Canada
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest - MarketBeat
SAB Biotherapeutics Launches New $75 Million ATM Program - The Globe and Mail
SAB Biotherapeutics Files $300 Million Mixed Shelf - MarketScreener
Sab Biotherapeutics files for offering of up to $300 mln - marketscreener.com
Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentumEarnings Season Recap & Minimal Capital Trading - bollywoodhelpline.com
SAB Biotherapeutics enters sales agreement with UBS SecuritiesSEC filing - marketscreener.com
SAB Biotherapeutics Enters Sales Agreement With UBS SecuritiesSEC Filing - TradingView — Track All Markets
SAB Biotherapeutics Establishes New At-the-Market Offering Program - TradingView — Track All Markets
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is SAB Biotherapeutics Inc. stock a good choice for value investorsBlue Chip Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
SABS SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics Earnings Notes - Trefis
Will SAB Biotherapeutics Inc. Equity Warrant stock continue dividend increases2025 Pullback Review & AI Forecasted Entry and Exit Points - Улправда
What margin trends mean for SAB Biotherapeutics Inc. stockJuly 2025 Setups & Verified Entry Point Detection - Улправда
Guggenheim Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
Will SAB Biotherapeutics Inc. stock continue dividend increases2025 Macro Impact & Weekly Chart Analysis and Trade Guides - DonanımHaber
Guggenheim Initiates Coverage on SAB Biotherapeutics With Buy Rating, $15 Price Target - marketscreener.com
Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential - Investing.com Canada
Will SAB Biotherapeutics Inc. Equity Warrant stock deliver consistent dividends2025 Risk Factors & Real-Time Chart Breakout Alerts - DonanımHaber
Will SAB Biotherapeutics Inc. Equity Warrant stock outperform international peers2025 Technical Overview & Community Verified Watchlist Alerts - Улправда
Why SAB Biotherapeutics Inc. stock is favored by top institutionsProfit Target & Low Risk High Reward Trade Ideas - Улправда
SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at Chardan Capital - Defense World
SAB Biotherapeutics (SABS) director Jay S. Skyler granted 150,000 stock options - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation - Nasdaq
SAB Biotherapeutics (SABS) director awarded 150,000 stock options for 2025 - Stock Titan
SAB Biotherapeutics grants director option for 150,000 shares at $3.99 | SABS SEC FilingForm 4 - Stock Titan
SAB Biotherapeutics (SABS) director gets 150,000 options at $3.99 - Stock Titan
SAB Biotherapeutics grants director options for 150,000 shares | SABS SEC FilingForm 4 - Stock Titan
SAB Biotherapeutics (SABS) director awarded 150,000 stock options - Stock Titan
Aug EndMonth: Is SAB Biotherapeutics Inc. stock a good choice for value investorsRisk Management & Long Hold Capital Preservation Plans - Улправда
Will SAB Biotherapeutics Inc. stock benefit from green energy trendsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial - TipRanks
SAB Biotherapeutics' (SABS) Buy Rating Reiterated at Chardan Capital - MarketBeat
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - The Manila Times
SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint - TipRanks
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - Investing News Network
SAB Biotherapeutics Confirms Positive Phase 1 Results for SAB-142, Advancing to Phase 2b Trial for Type 1 Diabetes Treatment - Quiver Quantitative
SAB Bio announces positive confirmatory clinical results - marketscreener.com
Early trial of new type 1 diabetes drug shows no serum sickness - Stock Titan
SABS Options Overview History for Sab Biotherapeutics Stock - Barchart.com
SAB Biotherapeutics (SABS) adds 24,180,000 shares to 2021 equity plan - Stock Titan
SAB Biotherapeutics, Inc. (SABS) CMO details RSU-related share withholding - Stock Titan
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - Investing News Network
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 - Quiver Quantitative
SAB Biotherapeutics (SABS) Stock Analysis Report | Financials & Insights - Benzinga
Institution Moves: Is Above Food Ingredients Inc. stock safe for conservative investorsNew Guidance & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Why analysts upgrade SAB Biotherapeutics Inc. Equity Warrant stockQuarterly Portfolio Review & Safe Swing Trade Setups - Newser
Will SAB Biotherapeutics Inc. Equity Warrant stock gain from lower inflationMarket Movers & Consistent Growth Equity Picks - Newser
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sab Biotherapeutics Inc Azioni (SABS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):